United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC cut its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 9.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,689 shares of the biotechnology company’s stock after selling 2,041 shares during the period. Corient Private Wealth LLC’s holdings in United Therapeutics were worth $6,591,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Newbridge Financial Services Group Inc. acquired a new stake in shares of United Therapeutics during the 4th quarter worth about $25,000. Brooklyn Investment Group purchased a new position in United Therapeutics in the third quarter valued at approximately $33,000. MassMutual Private Wealth & Trust FSB raised its holdings in United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 58 shares in the last quarter. Jones Financial Companies Lllp lifted its position in shares of United Therapeutics by 678.9% during the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after buying an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in shares of United Therapeutics in the 4th quarter valued at $131,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $896,950.62. This represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the sale, the director now directly owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 90,255 shares of company stock valued at $32,614,521. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $313.60 on Friday. United Therapeutics Co. has a one year low of $221.53 and a one year high of $417.82. The company has a market cap of $14.08 billion, a P/E ratio of 13.77, a PEG ratio of 0.97 and a beta of 0.64. The firm has a fifty day moving average of $346.14 and a two-hundred day moving average of $357.34.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the prior year, the company posted $4.36 earnings per share. As a group, equities analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on UTHR. UBS Group lifted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.